JP2010533181A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533181A5
JP2010533181A5 JP2010516053A JP2010516053A JP2010533181A5 JP 2010533181 A5 JP2010533181 A5 JP 2010533181A5 JP 2010516053 A JP2010516053 A JP 2010516053A JP 2010516053 A JP2010516053 A JP 2010516053A JP 2010533181 A5 JP2010533181 A5 JP 2010533181A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
tnfα
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010516053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/008458 external-priority patent/WO2009011782A2/en
Publication of JP2010533181A publication Critical patent/JP2010533181A/ja
Publication of JP2010533181A5 publication Critical patent/JP2010533181A5/ja
Withdrawn legal-status Critical Current

Links

JP2010516053A 2007-07-13 2008-07-10 ＴＮＦα阻害剤の肺投与のための方法及び組成物 Withdrawn JP2010533181A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95942607P 2007-07-13 2007-07-13
PCT/US2008/008458 WO2009011782A2 (en) 2007-07-13 2008-07-10 METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013220124A Division JP2014062095A (ja) 2007-07-13 2013-10-23 ＴＮＦα阻害剤の肺投与のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2010533181A JP2010533181A (ja) 2010-10-21
JP2010533181A5 true JP2010533181A5 (enExample) 2011-08-25

Family

ID=40260243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010516053A Withdrawn JP2010533181A (ja) 2007-07-13 2008-07-10 ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP2013220124A Pending JP2014062095A (ja) 2007-07-13 2013-10-23 ＴＮＦα阻害剤の肺投与のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013220124A Pending JP2014062095A (ja) 2007-07-13 2013-10-23 ＴＮＦα阻害剤の肺投与のための方法及び組成物

Country Status (7)

Country Link
US (1) US20090110679A1 (enExample)
EP (1) EP2173380A4 (enExample)
JP (2) JP2010533181A (enExample)
CN (1) CN101848733A (enExample)
CA (1) CA2693771A1 (enExample)
TW (1) TW200922618A (enExample)
WO (1) WO2009011782A2 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
CA2626804A1 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
MX2008012896A (es) 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
FR2909643B1 (fr) * 2006-12-11 2011-03-04 Valois Sas Dispositif de distribution de produit fluide
WO2008150491A2 (en) * 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
DK2230934T3 (da) 2007-12-14 2012-11-26 Aerodesigns Inc Afgivelse af aerosoliserbare næringsmiddelprodukter
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
WO2009143453A2 (en) * 2008-05-23 2009-11-26 The Lauridsen Group, Inc. Methods and compositions for reducing lung inflammation in an animal
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN102458517B (zh) 2009-04-29 2014-07-23 阿布维生物技术有限公司 自动注射装置
RU2560701C2 (ru) * 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
NZ600069A (en) 2009-12-15 2015-02-27 Abbvie Biotechnology Ltd Improved firing button for automatic injection device
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
GB201005064D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EA028899B1 (ru) 2010-04-30 2018-01-31 Алексион Фармасьютикалз, Инк. АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
HUE039740T2 (hu) 2010-06-03 2019-01-28 Abbvie Biotechnology Ltd Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
EP3187216B1 (en) 2011-01-24 2019-08-21 AbbVie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014018668A2 (en) * 2012-07-24 2014-01-30 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP2911664B1 (en) 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US20160051673A1 (en) 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
JP2016534976A (ja) * 2013-05-23 2016-11-10 アズセラピーズ インコーポレイテッド クロモリンを送達する方法
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2016031250A1 (en) * 2014-08-26 2016-03-03 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EP3463461A4 (en) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EA202090247A1 (ru) 2017-07-14 2020-05-12 Цитомкс Терапьютикс, Инк. Антитела против cd166 и их применения
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
KR20230066126A (ko) 2017-07-27 2023-05-12 알렉시온 파마슈티칼스, 인코포레이티드 고농도 항-c5 항체 제형
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
MX2020004284A (es) 2017-10-26 2020-10-28 Alexion Pharma Inc Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
KR20250174998A (ko) * 2018-03-08 2025-12-15 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis
ES2996257T3 (en) 2018-05-31 2025-02-12 Alexion Pharma Inc Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
AU2019370295A1 (en) 2018-10-30 2021-06-03 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
EP3893945A4 (en) 2018-12-10 2022-11-30 The General Hospital Corporation CROMOGLYC ESTERS AND THEIR USES
CN120005921A (zh) 2018-12-12 2025-05-16 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
KR20230005268A (ko) 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
JP7829595B2 (ja) 2021-04-09 2026-03-13 武田薬品工業株式会社 補体因子ｄを標的とする抗体及びその使用
CA3216770A1 (en) 2021-04-26 2022-11-03 Tomoki Yoshihara Anti-clec12a antibodies and uses thereof
CA3214355A1 (en) 2021-04-26 2022-11-03 Antara Banerjee Anti-adgre2 antibodies and uses thereof
TW202330612A (zh) 2021-10-20 2023-08-01 日商武田藥品工業股份有限公司 靶向ｂｃｍａ之組合物及其使用方法
CN116763763B (zh) * 2022-12-05 2024-08-30 齐鲁制药有限公司 一种司美格鲁肽吸入喷雾剂及其制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6000A (en) * 1849-01-02 Abunah s
GB9015522D0 (en) * 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6427682B1 (en) * 1995-04-05 2002-08-06 Aerogen, Inc. Methods and apparatus for aerosolizing a substance
US5826571A (en) * 1995-06-08 1998-10-27 Innovative Devices, Llc Device for use with metered dose inhalers (MDIS)
CA2378713C (en) * 1995-06-21 2003-08-12 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
JP2002505574A (ja) * 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
AU1251999A (en) * 1997-12-03 1999-06-16 Britannia Pharmaceuticals Limited Improvements in medicaments for asthma treatment
GB9827200D0 (en) * 1998-12-11 1999-02-03 Glaxo Group Ltd Dry powder inhaler
AU756677B2 (en) * 1999-03-02 2003-01-23 Centocor Inc. Anti-TNFalpha antibodies in therapy of asthma
JP2002541213A (ja) * 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10123749A1 (de) * 2001-05-16 2002-12-12 Inamed Gmbh Vorrichtung zum Verabreichen von Aerosolen
US20030012786A1 (en) * 2001-05-25 2003-01-16 Teoh Leah S. Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
EP1436030A1 (en) * 2001-10-08 2004-07-14 Eli Lilly And Company Portable medication inhalation kit
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
AU2002316574B2 (en) * 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
AU2006246721B2 (en) * 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2626804A1 (en) * 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
MX2008012896A (es) * 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
EP2666472A3 (en) * 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2007120626A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) * 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
CN103316402A (zh) * 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
BRPI0716762A2 (pt) * 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
NZ576133A (en) * 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
WO2008150491A2 (en) * 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
WO2008154543A2 (en) * 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) * 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
NZ600979A (en) * 2008-01-15 2014-01-31 Abbott Lab Improved mammalian expression vectors and uses thereof
BRPI0907186A2 (pt) * 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
US20100040630A1 (en) * 2008-03-24 2010-02-18 Aake Elden Methods and compositions for treating bone loss
RU2560701C2 (ru) * 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
EP2531613A2 (en) * 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
HUE039740T2 (hu) * 2010-06-03 2019-01-28 Abbvie Biotechnology Ltd Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére

Similar Documents

Publication Publication Date Title
JP2010533181A5 (enExample)
JP6200806B2 (ja) 二重特異的融合タンパク質
CN101711256B (zh) 针对il-25的抗体
EP4198055A1 (en) Antibody of il-11 and use thereof
JP2016512554A5 (enExample)
JP2005523946A5 (enExample)
CN114853888B (zh) 抗tslp纳米抗体及其应用
JP2013507131A5 (enExample)
CN102482352B (zh) 抗il-17br的抗体
JP2002539072A5 (enExample)
CN101848733A (zh) 用于肺部给予TNFα抑制剂的方法和组合物
JP2008521870A5 (enExample)
JP6469012B2 (ja) インターロイキン−６に対する抗体およびその使用
WO2021042694A1 (zh) 抗vegf单域抗体及其应用
AU2008334605A1 (en) Polypeptides, antibody variable domains & antagonists
KR20170093120A (ko) Rsv 감염의 치료 방법
US12012456B2 (en) Anti-interleukin-4 receptor (IL-4R) single-domain antibody, encoding polynucleotide and methods of making and using the antibody for IL-4R detection and disease treatment
CN103030687B (zh) 青环海蛇抗炎活性肽Hydrostatin-SN1及其编码基因和在制药中的应用
JPWO2006046661A1 (ja) インターロイキン−６阻害剤
CN117603358B (zh) 一种广谱新型冠状病毒的双特异性抗体
JP2017528454A5 (enExample)
JP2001526689A (ja) トロンボポエチンの新規な投与
WO2023040834A1 (zh) 一株羊驼源纳米抗体及其应用
AU2022303437A1 (en) Anti-trop2 single-domain antibody and use thereof
KR20110071139A (ko) Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드